Quantcast Acelity - KCI Announces Data Supporting Health Economic Benefits of TOUCHLESS CARE™ Zinc Oxide Protectant Spray
MENU

KCI Announces Data Supporting Health Economic Benefits of TOUCHLESS CARE™ Zinc Oxide Protectant Spray

Touchless zinc oxide spray provides ease-of-use for clinicians with reduced irritation

August 26, 2019 | SAN ANTONIO
KCI, an Acelity Company, today announced recently published data stemming from a publication search and computational model demonstrates significant annual hospital savings from the
use of TOUCHLESS CARE™ Zinc Oxide Protectant Spray versus standard of care (SOC).1

Incontinence-associated dermatitis (IAD), the most common form of moisture-associated skin damage (MASD), is a major concern with hospitalized patients and puts them at higher risk for skin breakdown and ulceration.2-4 Zinc oxide has traditionally been utilized to prevent and treat MASD/IAD.5,6 Conventional zinc oxide ointments have been applied with gloved hands directly to an area of concern, potentially leading to cross-contamination.
 
With TOUCHLESS CARE™ Zinc Oxide Protectant Spray, clinicians are able to treat an affected area without having to physically touch the patient, reducing risks for irritation and cross contamination.7

TOUCHLESS CARE™ Zinc Oxide Protectant Spray was created with a high percentage of silicone, allowing skin to breathe while staying lubricated, minimizing friction and facilitating easier clean-up. Designed with advanced concentrated formulas that optimize the therapeutic effect, and help maintain moisture balance, TOUCHLESS CARE™ Zinc Oxide Protectant Spray provides benefits for healthcare providers, including:
• Ease of application and removal,8
• Increased efficacy and patient compliance,8
• Eliminates the need to rub painful denuded skin,
• Thin layer allows for less product use per application,8 and
• Lower risk of cross contamination
 
“With healthcare costs continuing to rise, it is imperative that we work to provide solutions that maximize patient care, while also minimizing risk,” said Ronald Silverman, MD, FACS, Chief Medical Officer, KCI. “TOUCHLESS CARE™ Zinc Oxide Protectant Spray provides clinicians with an effective, breathable solution that provides complete coverage to an effected area without irritation, while also providing faster, easier application.”

“As healthcare providers, we are often looking for ways to provide quality care to an ever-growing number of patients in the same amount of time as before,” said Cathy Milne, MSN, APRN, CWOCN-AP, Connecticut Clinical Nursing Associates. “To combat the issue of time constraints versus quality care, I am always looking for ways to maximize effectiveness and increase efficiency at the same time. In my practice, TOUCHLESS CARE™ Zinc Oxide Protectant Spray has provided me the opportunity to up-level the care my patients are receiving, while cutting down on time of application – in turn leading to costand time-savings, without a reduction in quality of care.”
 
In a recent study entitled “Economic Model for Cost Containment: Evaluating the Utilization of a Touchfree Zinc Oxide in an Acute Care Hospital,” published in Cureus, computational model data demonstrated the use of TOUCHLESS CARE™ Zinc Oxide Protectant Spray led to hypothetical 250-bed acute care hospital cost savings between $181.88 to $2,000.63 per patient stay, and $4,728.88 to $52,016.25 over a 12-month period compared to traditional zinc oxide application.1
 
About TOUCHLESS CARE™ Spray Products
TOUCHLESS CARE™ Spray products are designed with advanced concentrated formulas that optimize the therapeutic effect and help maintain moisture balance.9 These formulations allow for the convenience of a spray application that eliminates the need to rub irritated, denuded skin.

About KCI, an Acelity Company
KCI, an Acelity Company, is a well trusted brand in advanced wound care. We are a leader in negative pressure wound therapy, providing solutions for both wound healing and surgical management. Our product offerings are available in more than 90 countries and deliver value through solutions that speed healing. KCI is a leader in quality, safety and customer experience and is committed to advancing the science of healing. Headquartered in San Antonio, Texas, KCI employs approximately 4,500 people worldwide.
 
References:
1. Tolentino A, Dick S: Economic Model for Cost Containment: Evaluating the Utilization of a Touch-free Zinc Oxide in an Acute Care Hospital. June 20, 2019. Cureus 11(6): e4957. doi:10.7759/cureus.4957

2. Bliss DZ, Zehrer C, Savik K, Smith G, Hedblom E: An economic evaluation of four skin damage prevention regimens in nursing home residents with incontinence: economics of skin damage prevention. J Wound Ostomy Continence Nurs. 2007, 34:143-152. 10.1097/01.WON.0000264825.03485.40

3. Gray M, Giuliano KK: Incontinence-associated dermatitis and immobility as pressure injury risk factors: a multisite epidemiologic analysis.
(Epub ahead of print). J Wound Ostomy Continence Nurs. 2017, 10.1097/WON.0000000000000390

4. Beeckman D, Van Lancker A, Van Hecke A, Verhaeghe S: A systematic review and meta-analysis of incontinence-associated dermatitis, incontinence, and moisture as risk factors for pressure ulcer development. Res Nurs Health. 2014, 37:204-218. 10.1002/nur.21593

5. Gray M, Beeckman D, Bliss DZ, et al.: Incontinence-associated dermatitis: a comprehensive review and update. J Wound Ostomy Continence Nurs. 2012, 39:61-74. 10.1097/WON.0b013e31823fe246

6. Kon Y, Ichikawa-Shigeta Y, Iuchi T, et al.: Effects of a skin barrier cream on management of incontinence-associated dermatitis in older women: a cluster randomized controlled trial. J Wound Ostomy Continence Nurs. 2017, 44:481-486. 10.1097/WON.0000000000000353

7. CHG compatibility of TOUCHLESS CARE™ SPRAY range. CHC R293. June 2015. Crawford Healthcare Ltd.

 
8. Roberts S. et al. A comparison of the application, removal and cost effectiveness of zinc oxide barrier products. Poster presentation: Symposium on Advanced Wound Care: April 2016.

9. Nolan, K. and Murmur, E. Moisturizers: Reality and the Skin benefits. Dermatologic Therapy. 2012;(25):229-233.
 

For more information, contact:

Maggie Fairchild
Corporate Communications
Phone: +1-210-330-2666
Email: maggie.fairchild@acelity.com
 
Caleb Moore
Investor Relations
Phone: +1 210-255-6433
Email: caleb.moore@acelity.com
 

Footer Navigation